Clinically and orally compatible formulation-manufactured DDX5 (p68)-targeting molecular glue FL118 products exhibit low toxicity but high efficacy against human cancer

[Display omitted] •FL118 drug substances (DS) exhibited high chemical stability under various test conditions.•Clinically and orally compatible FL118 drug products (DP) were manufactured using patent-protected intellectual property.•Toxicology studies in rats and dogs showed that the clinically and orally compatible FL118 DP exhibit favorable toxicity.•The clinically and orally compatible FL118 DP exhibited exceptional efficacy against human CRC, osteosarcoma, CRPC and PDAC.